Skip to main content
CRBP
NASDAQ Life Sciences

Corbus Details Full CANYON-1 Data: 5% Weight Loss at 60 mg, Clean Psychiatric Safety

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.448
Mkt Cap
$69.857M
52W Low
$2.81
52W High
$12.881
52W Position info
23% above low
Off High info
73% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

CRBP sits 23% above its 52-week low of $2.81.

Summary

Corbus presented the full CANYON-1 Phase 1b dataset for CRB-913 at ObesityWeek 2026: 5.0% mean weight loss at 60 mg at 12 weeks (p<0.0001 vs placebo), no serious or severe psychiatric events, and 8.3% discontinuation due to adverse events. The company will now take the plan to the FDA.


Key Events · Product Development and Regulatory · CRBP

  • Full CANYON-1 Dose-Response Disclosed

    LS mean weight loss at week 12 was 2.8% (20 mg), 3.3% (40 mg) and 5.0% (60 mg) versus 0.0% for placebo, all p<0.0001, with no evidence of plateauing at any dose.

  • Psychiatric Safety Clean at All Doses

    No serious or severe treatment-emergent psychiatric AEs and zero suicidality across 188 participants on CRB-913; only one moderate depressive-symptom case, and anxiety ranged 3.1%-8.2%, in line with published GLP-1 data.

  • Tolerability Comparable to GLP-1s

    Treatment discontinuation due to AEs was 8.3% overall (21 of 254), and GI events were all mild or moderate with no serious or severe cases; nausea at 60 mg was 22.6% versus 47% for oral semaglutide 25 mg in published data.

  • FDA Engagement Is Next Step

    Corbus plans to engage the FDA on the CRB-913 development plan and evaluate combination studies with GLP-1 therapies; no timeline was disclosed.


Analysis · CRBP · Life Sciences

The headline 5% weight-loss figure was already out in September, so the stock-moving question is whether the full dataset holds up — and it does. All three doses beat placebo with p<0.0001, the 60 mg cohort lost 5.0% at 12 weeks with no plateau, and 44.4% of completers at that dose lost at least 5.0%. Just as important for a CB1 drug, the psychiatric profile that sank prior molecules in this class did not appear: zero suicidality, zero severe or serious psychiatric events, and only one moderate depressive-symptom case among 188 treated participants. Discontinuations due to adverse events ran 8.3% overall, in line with GLP-1 benchmarks, and GI events were milder than oral GLP-1 labels. That combination — oral, non-incretin, tolerable — is the whole investment case for CRB-913, and the detail supports it. The company now says it will engage the FDA on the development plan and evaluate GLP-1 combinations, which is the next real checkpoint; no timing was given. Against $115M of cash at September 30 and a widening quarterly loss, the program still needs a partner or fresh capital to reach later-stage trials.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRBP was trading at $3.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69.9M. The 52-week trading range was $2.81 to $12.88. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRBP - Latest Insights

CRBP
Nov 10, 2026, 8:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.52
Real-time Price: $3.45 info
Change: -$0.0725 (-2%) info
Market Cap: $69.857M info
CRBP
Sep 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.08
Real-time Price: $3.45 info
Change: -$3.63 (-51%) info
Market Cap: $69.857M info
CRBP
Sep 14, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.26
Real-time Price: $3.45 info
Change: -$5.81 (-63%) info
Market Cap: $69.857M info
CRBP
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $8.91
Real-time Price: $3.45 info
Change: -$5.46 (-61%) info
Market Cap: $69.857M info
CRBP
Aug 07, 2026, 4:33 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $9.77
Real-time Price: $3.45 info
Change: -$6.32 (-65%) info
Market Cap: $69.857M info